Scarica l'app Stockscreener
98.66
2.00%
-2.01
Dopo l'orario di chiusura:
98.25
-0.41
-0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$100.67
Aprire:
$100.35
Volume 24 ore:
1.66M
Relative Volume:
0.81
Capitalizzazione di mercato:
$11.20B
Reddito:
$1.51B
Utile/perdita netta:
$348.84M
Rapporto P/E:
35.48
EPS:
2.7805
Flusso di cassa netto:
$667.65M
1 W Prestazione:
-4.33%
1M Prestazione:
+31.46%
6M Prestazione:
+24.19%
1 anno Prestazione:
+50.53%
Intervallo 1D:
$98.13
$100.83
Intervallo di 1 settimana:
$98.13
$104.78
Portata 52W:
$61.23
$104.78
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
98.66 | 11.55B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Downgrade | Goldman | Neutral → Sell |
| 2025-10-14 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call - Yahoo Finance
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Halozyme (HALO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Wedge Capital Management L L P NC Invests $31.61 Million in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Handelsbanken Fonder AB Grows Stake in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week HighHere's What Happened - marketbeat.com
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - Yahoo Finance Australia
Halozyme director Connaughton sells $167,152 in shares By Investing.com - Investing.com Nigeria
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock - marketbeat.com
Halozyme director Connaughton sells $167,152 in shares - Investing.com
Halozyme Therapeutics (HALO) affiliate plans stock option-related share sales in Form 144 - Stock Titan
Halozyme Therapeutics (HALO) director sells 1,626 shares in Rule 10b5-1 plan trade - Stock Titan
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance - Yahoo Finance
What Halozyme Therapeutics (HALO) Guidance Raise Means For Valuation - Sahm
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know - Yahoo Finance
Halozyme Therapeutics (HALO) insider schedules 1,626-share stock sale via trading plan - Stock Titan
Halozyme Therapeutics (HALO) Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE DealsHas The Bull Case Changed? - Sahm
Biotech Stocks At 52-Week HighsHALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE - RTTNews
Gradient Investments LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth and Strong Analyst Support - DirectorsTalk Interviews
HALO Surges As Halozyme Hikes 2026 Guidance And Wins Upgrades - timothysykes.com
Earnings Update: Halozyme Therapeutics, Inc. Beat Earnings And Now Analysts Have New Forecasts For This Year - moomoo.com
Oliver Luxxe Assets LLC Trims Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks - Yahoo Finance
Halozyme Therapeutics (HALO) Stock Looks Expensive At Today’s Price - Sahm
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise? - Yahoo Finance
HALO Surges As Halozyme Lifts 2026 Outlook And Wins Upgrades - timothysykes.com
Halozyme Therapeutics (NASDAQ:HALO) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat
Assenagon Asset Management S.A. Has $78.09 Million Position in Halozyme Therapeutics, Inc. $HALO - marketbeat.com
Halozyme (HALO) Stock Rallies As Royalties Surge And Guidance Climbs - Sahm
Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlig - GuruFocus
Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ... - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Given New $105.00 Price Target at TD Cowen - marketbeat.com
Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Raised to $99.56, Implies 16% Upside - TradingView
HALO Surges As Halozyme Hikes 2026 EPS And Revenue Outlook - StocksToTrade
Halozyme Therapeutics HALO Surges After Big Earnings Beat And Guidance Hike - StocksToTrade
Halozyme Therapeutics Inc. (HALO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up - Yahoo Finance
Citizens Jmp Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00 - marketbeat.com
HALOZYME THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $110 FROM $83 - Bitget
Why Halozyme Therapeutics Is Surging 14.9%: Wells Fargo Maintains Equal-Weight - AlphaStreet
Halozyme Therapeutics (NASDAQ:HALO) Sees Large Volume Increase on Strong Earnings - marketbeat.com
Wells Fargo & Company Boosts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $95.00 - marketbeat.com
Halozyme Therapeutics (NASDAQ:HALO) Upgraded to "Outperform" at Leerink Partners - MarketBeat
Halozyme Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $115.00 - marketbeat.com
Halozyme Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:HALO) 2026-08-07 - Seeking Alpha
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):